Legend Biotech Corporation is a global biotechnology company, which is focused on developing, manufacturing and commercializing novel therapies to treat life-threatening diseases. The Company is developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), is a CAR-T cell therapy for the treatment of multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also developing an allogeneic gamma delta CAR-T product candidate targeting B-cell maturation antigen for MM.
More about the company